Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs

Bild1-long23

 


Within the project Horizon Scanning in Oncology 9 databases are frequently scanned to identify new/emerging oncologic drugs. Every 3 months, these drugs are filtered according to predefined criteria (i.e. in most instances availability of phase III study results) and are then prioritised by an expert panel to identify those therapies for which either a substantial clinical or financial impact can be expected.

HSO Priorisation No. 41

HSO Priorisation No. 40

HSO Priorisation No. 39

HSO Priorisation No. 38

HSO Priorisation No. 37

HSO Priorisation No. 36

HSO Priorisation No. 35

HSO Priorisation No. 34

HSO Priorisation No. 33

HSO Priorisation No. 32

HSO Priorisation No. 31

HSO Priorisation No. 30

HSO Priorisation No. 29

HSO Priorisation No. 28

HSO Priorisation No. 27

HSO Priorisation No. 26

HSO Priorisation No. 25

HSO Priorisation No. 24

HSO Priorisation No. 23

HSO Priorisation No. 22

HSO Priorisation No. 21

HSO Priorisation No. 20

HSO Priorisation No. 19

HSO Priorisation No. 18